Core Viewpoint - The company held its first extraordinary general meeting of shareholders in 2026, where all proposed resolutions were approved without any rejections [2][4]. Group 1: Meeting Details - The meeting was convened on February 26, 2026, at a location in Shanghai [5]. - The meeting was chaired by Mr. Yaolin Wang and utilized a combination of on-site and online voting methods, complying with the Company Law and the company's articles of association [2][4]. Group 2: Attendance and Legal Verification - All nine current directors and the company secretary attended the meeting, along with other senior management [3]. - The meeting was witnessed by lawyers from JunHe Law Offices, who confirmed that the procedures followed were in accordance with relevant laws and regulations, and the resolutions made were valid [6]. Group 3: Financial Performance Overview - For the fiscal year 2025, the company expects to achieve a revenue of 37.3253 million yuan, with a net loss attributable to shareholders of approximately 316.8384 million yuan [8][13]. - The decline in revenue is attributed to variations in income from technology licensing and cooperation, which differ from year to year [13]. Group 4: Operational Insights - The company's performance in 2025 was significantly influenced by its high level of research and development (R&D) investment, with several core clinical projects reaching critical stages [11]. - The company is advancing multiple clinical trials, including a Phase III trial for D-0502 and various trials for D-2570 and D-0120, indicating a robust pipeline [11][12]. Group 5: Financial Data Summary - The company anticipates a gross profit of approximately -316.5959 million yuan and a total profit of -316.5989 million yuan for 2025, reflecting an increase in losses compared to the previous year [13]. - The expected net loss after excluding non-recurring items is projected to be around -328.8111 million yuan [13].

Group 1 - The company anticipates a total profit loss of 291.82 million yuan for the year 2025, with a net profit attributable to the parent company expected to be -292.20 million yuan, and a net profit after deducting non-recurring gains and losses projected at -304.41 million yuan [3] - The expected operating revenue for 2025 is 37.25 million yuan, which is below 100 million yuan [3] - The company reported a total profit loss of 240.20 million yuan for the year 2024, with a net profit attributable to the parent company also at -240.20 million yuan [5] Group 2 - The significant changes in performance for 2025 are primarily influenced by the intensity of research and development (R&D) investment and the composition of revenue [7] - The company is advancing multiple core clinical projects, including D-0502, D-2570, and D-0120, which are in various stages of clinical trials [7] - The company has made key progress in its preclinical pipeline with two innovative candidates, YF087 and YF550, showing promising anti-tumor potential [7][8] Group 3 - The company maintains high levels of R&D investment, but its current revenue mainly comes from licensing and collaboration, which varies from year to year [8] - The income from technology licensing and collaboration is currently insufficient to cover costs and expenses, leading to expected continued losses in 2025 [8] - Despite the anticipated losses, the company's core business and competitive strengths have not experienced significant adverse changes [8]

Core Viewpoint - The company Yifang Biotech (688382.SH) has announced an expected net loss of 292 million yuan for the fiscal year 2025, primarily due to high R&D investment and revenue composition changes [1]. Group 1: Financial Performance - The company anticipates a net loss of 292 million yuan for 2025 [1]. - The financial performance is significantly influenced by the intensity of R&D investments and the structure of revenue [1]. Group 2: R&D Progress - The company is advancing multiple core clinical projects, with several entering critical stages and showing positive progress [1]. - The oral selective estrogen receptor degrader (SERD) D0502 is undergoing a Phase III clinical trial for second-line treatment in China [1]. - The TYK2 inhibitor D-2570 has initiated clinical explorations in various autoimmune diseases, including a Phase II trial for ulcerative colitis and a Phase III trial for psoriasis in China, as well as a Phase I trial in the U.S. [1]. - The URAT1 inhibitor D-0120 has completed follow-up in a Phase II clinical trial in the U.S. and is expected to finish all research work by Q1 2026 [1]. Group 3: Preclinical Pipeline - The company has made significant progress in its preclinical pipeline, with two innovative candidates, WRN inhibitor YF087 and KIF18A inhibitor YF550, demonstrating strong anti-tumor potential in various preclinical studies [2]. - Ongoing IND supportive research is being conducted to prepare these candidates for clinical stages [2]. - The company continues to invest in early-stage R&D, including the development of other candidate drugs, innovative technology platforms, and early drug discovery to build momentum for long-term growth [2].

Core Viewpoint - The company Yifang Biotech (688382.SH) has announced an expected net loss of 292 million yuan for the fiscal year 2025, primarily due to high R&D investment and revenue composition changes [1]. Group 1: Financial Performance - The company anticipates a net loss of 292 million yuan for 2025 [1]. - The financial performance is significantly influenced by the intensity of R&D investments and the structure of revenue [1]. Group 2: R&D Progress - The company is advancing multiple core clinical projects, with several entering critical stages and showing positive progress [1]. - The oral selective estrogen receptor degrader (SERD) D0502 is undergoing a Phase III clinical trial for second-line treatment in China [1]. - The TYK2 inhibitor D-2570 has initiated clinical explorations in various autoimmune diseases, including a Phase II trial for ulcerative colitis and a Phase III trial for psoriasis in China, as well as a Phase I trial in the United States [1]. - The URAT1 inhibitor D-0120 has completed follow-up in a Phase II clinical trial in the U.S. and is expected to finish all research work by the first quarter of 2026 [1]. Group 3: Preclinical Pipeline - The company has made significant progress in its preclinical pipeline, with two innovative candidates, WRN inhibitor YF087 and KIF18A inhibitor YF550, demonstrating strong anti-tumor potential in various preclinical studies [2]. - Ongoing IND supportive research is being conducted to prepare these candidates for clinical stages [2]. - The company continues to invest in early-stage R&D, including the development of other candidate drugs, innovative technology platform construction, and early drug discovery to build momentum for long-term growth [2].

Core Viewpoint - The company Yifang Biotech (688382.SH) is expected to report significant losses in 2025, with a projected total profit of -292 million yuan and a net profit attributable to shareholders of -292 million yuan, indicating ongoing financial challenges as it invests heavily in research and development [1][2]. Financial Performance - The company anticipates a revenue of 37.2452 million yuan in 2025, which is below 100 million yuan, reflecting a challenging revenue environment [1]. - The expected net profit after deducting non-recurring gains is projected to be -304 million yuan, indicating a worsening financial outlook [1]. Research and Development Progress - The company is maintaining high levels of R&D investment, with several core clinical projects advancing to critical stages, including the D-0502 SERD in Phase III trials and D-2570 TYK2 inhibitor in multiple clinical explorations [1][2]. - Two innovative preclinical candidates, YF087 and YF550, are showing promising anti-tumor potential and are undergoing IND supportive research to prepare for clinical stages [2]. Revenue Sources and Business Model - The current revenue primarily comes from licensing and collaboration, which varies year to year, leading to fluctuations in income that do not cover costs and expenses, resulting in continued losses for 2025 [2]. - Despite the financial losses, the company's core business and competitive strengths remain intact, indicating potential for future recovery as R&D progresses [2].

Core Viewpoint - The company Yifang Biotech (688382.SH) is expected to report significant losses in 2025, with a projected total profit of -292 million yuan and a net profit attributable to shareholders of -292 million yuan, indicating ongoing financial challenges as it invests heavily in R&D [1] Group 1: Financial Projections - The company anticipates a revenue of 37.25 million yuan in 2025, which is below 100 million yuan [1] - The projected net profit after excluding non-recurring gains and losses is expected to be -304 million yuan [1] Group 2: R&D Investments - The primary reason for the performance changes in 2025 is attributed to the intensity of R&D investments and the composition of revenue [1] - The company maintains high levels of R&D spending as it advances multiple core clinical projects, including D-0502, D-2570, and D-0120, which are in various stages of clinical trials [1][2] Group 3: Clinical Pipeline Progress - The company has made significant progress in its preclinical pipeline, with two innovative candidates, YF087 and YF550, showing promising anti-tumor potential and currently undergoing IND supportive research [2] - The company continues to invest in early-stage R&D, including the development of other candidates and innovative technology platforms, to build momentum for long-term growth [2] Group 4: Revenue Sources and Challenges - The current revenue primarily comes from licensing and collaboration, which varies from year to year, leading to fluctuations in income [2] - Despite the anticipated losses in 2025, the company's core business and competitive strengths have not experienced significant adverse changes [2]